Exchange: NASDAQ·Updated 07:39 PM EDT

INTS INTENSITY THERAPEUTICS, INC.

$3.92
$0.23
(5.93%)
Today
Closed $4.11
$0.1917
(4.66%)
After Hours
Reported EarningsAug 11
Mkt Cap$12.67M
Vol45,213.00

About INTS

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
49

Neutral Sentiment

How do you feel about INTS?

Advertisement|Remove ads.